Brief: Cocrystal Pharma Doses First Subjects In Clinical Study Of Cdi-988 For Pandemic Norovirus And Coronavirus
28/09/2023 13:06
Sept 28 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA DOSES FIRST SUBJECTS IN CLINICAL STUDY OF
CDI-988 FOR PANDEMIC NOROVIRUS AND CORONAVIRUS
Source text for Eikon: ID:nGNX6L01xZ
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway